Abrocitinib Shows Faster Itch Relief Than Dupilumab in Atopic Dermatitis

Severe pruritus remains the primary driver of morbidity and sleep disturbance in atopic dermatitis, often dictating the success or failure of a treatment regimen [1, 2]. While traditional management relied heavily on topical corticosteroids, the therapeutic landscape has expanded to include targeted biologics and oral Janus kinase 1 (JAK1) inhibitors [3, 4]. These systemic options vary significantly in their molecular targets, speed of symptom onset, and safety profiles, creating a complex decision-making process for the practicing clinician [5, 6]. Current evidence suggests that while both classes are highly effective, they offer different trajectories for symptomatic relief and quality-of-life improvements [7, 8]. A recent pooled analysis examines how the depth and speed of itch relief achieved by these distinct mechanisms directly influence broader patient-reported outcomes, offering clinicians clearer expectations for symptom resolution.